Antigen-based metric could better predict which patients benefit from immunotherapy, study says
Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help only a small subset of patients, meaning doctors often have to resort to a trial-and-error process to determine who might actually benefit from the novel treatments.
Now, scientists have developed a new metric they believe can help predict whether patients will respond to a class of immunotherapies known as checkpoint inhibitors, drugs that train the body’s natural defenses on cancer cells.
